Top Markets
Coin of the day
Poolbeg Pharma PLC Poolbeg Pharma PLC

Poolbeg Pharma PLC

POLB
Clasificación en acciones #38625
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Precio por acción
$0.11565963
Capitalización bursátil
$882.99K
Cambio (1 día)
-2.30%
Cambio (1 año)
189.81%
País
GB
Comercio Poolbeg Pharma PLC (POLB)

Categoría

Ratio P/S de Poolbeg Pharma PLC (POLB)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Poolbeg Pharma PLC, el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de Poolbeg Pharma PLC desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE